SPARQL
Downloads
Documentation/Help
Skip Header
Results
Your Query
Add common prefixes
DESCRIBE <http://purl.uniprot.org/SHA-384/6961EB4FA57811919FC989DE0DC3BC2AC998F8870E6F53AE09F3AC945A7553CF845BB48C0542BDB587981803572B7EB1>
Submit Query
Cancel
RDF/XML
NTriples
Turtle
Show query
Share
Subject
Predicate
Object
http://purl.uniprot.org/SHA-384/6961EB4FA57811919FC989DE0DC3BC2AC998F8870E6F53AE09F3AC945A7553CF845BB48C0542BDB587981803572B7EB1
http://www.w3.org/1999/02/22-rdf-syntax-ns#type
http://purl.uniprot.org/core/Annotation
http://purl.uniprot.org/SHA-384/6961EB4FA57811919FC989DE0DC3BC2AC998F8870E6F53AE09F3AC945A7553CF845BB48C0542BDB587981803572B7EB1
http://www.w3.org/2000/01/rdf-schema#comment
"Data show that CEP-28122 is a highly potent and selective orally active anaplastic lymphoma kinase (ALK) inhibitor and selective against ALK-positive human cancer cell growth."
xsd:string
http://purl.uniprot.org/uniprot/#_9C01A9962E3A12A72398ABEEB889A0AB8E8CEE1A77C2FFC49F3FE938878FEC2C22960681541498AF24E205E9AB0676AB
http://www.w3.org/1999/02/22-rdf-syntax-ns#subject
http://purl.uniprot.org/SHA-384/6961EB4FA57811919FC989DE0DC3BC2AC998F8870E6F53AE09F3AC945A7553CF845BB48C0542BDB587981803572B7EB1
http://purl.uniprot.org/uniprot/B6D4Y2
http://purl.uniprot.org/core/mappedAnnotation
http://purl.uniprot.org/SHA-384/6961EB4FA57811919FC989DE0DC3BC2AC998F8870E6F53AE09F3AC945A7553CF845BB48C0542BDB587981803572B7EB1
http://purl.uniprot.org/uniprot/#_B6D4Y2-mappedCitation-22203728
http://purl.uniprot.org/core/mappedAnnotation
http://purl.uniprot.org/SHA-384/6961EB4FA57811919FC989DE0DC3BC2AC998F8870E6F53AE09F3AC945A7553CF845BB48C0542BDB587981803572B7EB1